Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
Neo Performance Materials Q3 Earnings Call Highlights
NeoGenomics to Participate in Upcoming Investor Conferences
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
NEO Battery Reports Fiscal Year 2027 Second Quarter Results
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics Reports Third Quarter 2026 Results
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics (NASDAQ:NEO) Hits New 12-Month High After Analyst Upgrade
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212